Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
dc.contributor.author | Kantarjian, Hagop | en_US |
dc.contributor.author | O'Brien, Susan | en_US |
dc.contributor.author | Talpaz, Moshe | en_US |
dc.contributor.author | Borthakur, Gautam | en_US |
dc.contributor.author | Ravandi, Farhad | en_US |
dc.contributor.author | Faderl, Stefan | en_US |
dc.contributor.author | Verstovsek, Srdan | en_US |
dc.contributor.author | Rios, Mary Beth | en_US |
dc.contributor.author | Shan, Jianqin | en_US |
dc.contributor.author | Giles, Francis | en_US |
dc.contributor.author | Cortes, Jorge | en_US |
dc.date.accessioned | 2007-09-20T18:23:32Z | |
dc.date.available | 2008-09-08T14:25:13Z | en_US |
dc.date.issued | 2007-04-15 | en_US |
dc.identifier.citation | Kantarjian, Hagop; O'Brien, Susan; Talpaz, Moshe; Borthakur, Gautam; Ravandi, Farhad; Faderl, Stefan; Verstovsek, Srdan; Rios, Mary Beth; Shan, Jianqin; Giles, Francis; Cortes, Jorge (2007)."Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure." Cancer 109(8): 1556-1560. <http://hdl.handle.net/2027.42/55988> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55988 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17342766&dopt=citation | en_US |
dc.description.abstract | BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. METHODS. The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies. RESULTS. The estimated 3-year survival rates were 72% in 88 patients who progressed in chronic phase, 30% in 130 patients who progressed in accelerated phase, 7% in 156 patients who progressed in blastic phase, and 75% in 37 patients in chronic phase with imatinib intolerance. Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others (estimated 2-year survival rates 100% vs 72% vs 67%; P = .01), but not in accelerated-blastic phase. CONCLUSIONS. Prognosis post-imatinib failure in chronic phase is reasonable; it is poor if the CML phase post-imatinib failure is accelerated or blastic. Cancer 2007. © 2007 American Cancer Society. | en_US |
dc.format.extent | 155421 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas ; Fax: (713) 792-2031 ; Department of Leukemia, Box 428, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.identifier.pmid | 17342766 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55988/1/22569_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.22569 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.